前苏联专利SU1739852A3 Method for synthesis of peptides or their pharmaceutically acceptable salts

专利PDF首页>>前苏联专利

专利附录

专利说明

权利要求

类似技术

同族专利

引用文献

法律状态

优先权

专利摘要:
Compounds of formula wherein R' represents alkyl having an α-amino or protected α-amino substituent and an aryl, heterocyclic or heterocyclic- dithio substituent; R2 represents a variety of aliphatic and cycloaliphatic hydrocarbon groups, which may be substituted; R3 represents isobutyl, sec-butyl, benzyl or (C3-CS cyclo- elkyl)methyl; and X represents a group of formula -CH(-A-R")-Y) (in which: A represents a single bond or an alkylene group: R4 represents an optionally protected carboxy group, an optionally N-substituted carbamoyl group, an optionally N-substituted carbazoyl group or an acyl group; and Y represents a hydroxy group, a mercapto group or a formyl group), or a group of formula -P(O)(R5)-OH (in which R5 represents an alkyl group having at least one optionally protected carboxy, N-substituted carbamoyl, optionally N-substituted carbazoyl, C2-C7 aliphatic carboxylic acyl or aromatic carboxylic acyl substituent)]; and their salts are renin inhibitors, which may be used in the treatment of angiotensin-induced hypertension.
公开号:SU1739852A3
申请号:SU853860201
申请日:1985-02-01
公开日:1992-06-07
发明作者:Матсуеда Рей；Ябе Юнтиро；Ямазаки Митсуо；Кокубу Татсуо；Хивада Кунио
申请人:Санкио Компани Лимитед (Фирма)；
IPC主号:

专利说明:

Sn Fri Sat Sn (Sn2 Sn (Yn-co2 Sn2b)) Sl-Sn Sn Fri and take off;
RZ (C4.) Alkyl, thiazolyl (C "-C4) alkyl, imidazolylmethyl; isobutyl, cyclohexylmethyl; X is the group CH (ACC) OH; A is a methylene group; U f - group
-SOYNCH2CH2-LUCHN2-CH2-0-CH2-CH2
-CO-MH-CH2CH-CH2CH3; CH3 CH3
-so-mn-ns-sd-sd-2
CH2OH
This invention relates to a method for producing peptides — new biologically active compounds that can be used in medicine.
or their Pharmaceutically acceptable salts, which have renin-inhibitory activity. The goal is to develop a method for obtaining more active compounds of the indicated class. The preparation is carried out by the reaction of carboxylic acid, f-ly of Rj-CO-NH-ClKR.j) -COOH, where RJ and R- are indicated above, or its reactive derivative with the amino compound of the phyla-CH (R3) -X, where X and R3 are listed above. 1 tab.
-vj
WITH
with
00
ate
Yu
The purpose of the invention is a method for producing new peptide derivatives - low-toxic compounds that have high renin-inhibiting / Ponpe
ACTIVITY.
Example 1. (S) - (N-BeH-1 and hydroxycarbonyl) -3- (G-naphthyl) -b-ala-mil-b-leucyl amino-3 (B) -oxy-6-methylpentanoyl | -T- -isoleucine (compound 1).
ABOUT
ghCH2OC-NH
soshgon
CONH-
a) M-Benzyloxy, rbonyl-3 (1-naphthyl) -T -.- alanyl-b-leucine.
3.49 g (10 mmol) of N-benzyloxycarbonyl-3- (1-naphthyl) -alanine and 1.21 g (12 mmol) of N-methylmorpholine are dissolved in 30 ml of anhydrous tetrahydrofuran, and then with simultaneous cooling 1.50 g (12 mmol) of ethyl chlorocarbonate are added dropwise with stirring to 5 ° C over 15 minutes. 2.35 g is then added.
C27H 2N4 ° 4.
Found,%: C 68,32; H 6.73; 20 N 11.90
b) H | 4 (5) -Ј5-Benzyloxycarboni 3 (1-naphthyl) -b-alanyl-b-leucil Ho-3 (S) -oxy-6-methylheptanoyl-L-isoleucinol.
25 77 mg d mmol) of hydrazide, prepared in accordance with the description given at stage a, the solution in 8 ml of dimethylformamide, then the solution is cooled to -60 ° С “Next,
(12 mmol) L-leucine hydrochloride, ethy- 30 Solution ° P 0.84 ml 4.0 n is added.
solution of hydrogen chloride in di and 0.18 ml of isoamyl nitrite. The reaction temperature was then raised to -20 ° C with stirring for 10 minutes. The disappearance of the hydrazide is observed, and then the product temperatures are again lowered to -60 ° C. In order to neutralize the solution and to obtain a solution of N-benzyl carbonyl-3 (1-naphthyl) -b-alanylH-leucine hydrazide, to the mixture is added 0, 45 g of N-methylmorpholine
of the crude ester, which is pre-suspended in 10 ml of methylene chloride and neutralized with 1.21 g (12 mmol) of N-methylmorpholine. The mixture is stirred for 2 hours while cooling with ice, and then incubated overnight at room temperature. It is then subjected to condensation by evaporation under reduced pressure. Water is added to the residue, and the precipitated oily material is extracted with ethyl acetate. The organic extract is washed with 1N . a solution of hydrochloric acid, water, a 5% aqueous solution of sodium bicarbonate and a saturated aqueous solution of sodium chloride in this order, and then dried over anhydrous sodium sulfate
35
solution of hydrogen chloride in dioxon and 0.18 ml of isoamyl nitrite. The reaction temperature is then raised to -20 ° C with stirring for 10 minutes. The disappearance of the hydrazide is observed, and then the temperature of the product is lowered again to -60 ° C. In order to neutralize the solvent and to obtain a solution of N-benzyloxy carbonyl-3 (1-naphthyl) -b-alanylH-leucine hydrazide, 0.45 g of N-methylmorpholine is added to the mixture
At the same time, the tert-butoxycarbonyl group is removed from 5,412 mg (1.1 mmol) of 4 (3) -tert-butoxycarbonylamino-3 (8) -oxy-6-methyl-heptanoyl-b. isoleucine with 6 n. solution of hydrogen chloride in dioxane. 4 (8) hydrochloride is obtained. The solvent is distilled off under reduced JQ amino 3 (3) -oxy-6-methylheptanoyl pressure. The thus obtained N-benzyloxycarbonyl-3- (1-naphthyl) -L-alanyl-b-leucine ethyl the ester as a syrup is dissolved in 30 ml of dimethylformamide and 5.06 g (100 mmol) of hydrazine hydrate is added to the resulting solution. The mixture obtained in the resulting solution of these procedures is stirred for 36 hours at room temperature. 55
isoleucine "Next, this product was dissolved in 5 ml of dimethylformamide and the resulting solution was added to the hydrazide solution, then the mixture was stirred at 4 ° C for 7 days. The solvent is distilled off under reduced pressure. About the resulting residue is added water and a particulate material obtained in the temperature. Then the reaction product is subjected to condensation at room temperature. The reaction product is then condensed by evaporation under reduced pressure, and water is added to the residue. The resulting colorless crystals are collected by filtration, washed thoroughly with water, and then dried in a desiccator, resulting in a yield of 4.23 g of solenoid from the title of the example, which melts at 200-204 ° C.
Elemental analysis.
Calculated,%: C 68, H 6.77; N 11.76
C27H 2N4 ° 4.
Found,%: C 68,32; H 6.73; N 11.90
b) H | 4 (5) -Ј5-benzyloxycarbonyl-3 (1-naphthyl) -b-alanyl-b-leucyl amy-Ho-3 (S) -oxy-6-methylheptanoyl-L-isoleucinol.
77 mg d mmol) of the hydrazide obtained in accordance with the description given in step a are dissolved in 8 ml of dimethylformamide, then the solution is cooled to -60 ° C. Next, in
Solution ° P Add 0.84 ml 4.0 n.
solution of hydrogen chloride in dioxane and 0.18 ml of isoamyl nitrite. Then the reaction temperature was raised to -20 ° C with stirring for 10 minutes. The disappearance of the hydrazide is observed, and then the temperature of the product is lowered again to -60 ° C. In order to neutralize the solution and obtain a solution of N-benzyloyl-carbonyl-3 (1-naphthyl) -b-alanylH-leucine hydrazide, 0.45 g of N-methylmorpholine is added to the mixture
At the same time, the tert-butoxycarbonyl group is removed from 412 mg (1.1 mmol) of 4 (3) -tert-butoxycarbonylamino-3 (8) -oxy-6-methyl-heptanoyl-b-isoleucinol using 6 n. solution of hydrogen chloride in dioxane. 4 (8) amino 3 (3) -oxy-6-methylheptanoyl-Lamino 3 (3) -oxy-6-methylheptanoyl-b hydrochloride is obtained.
isoleucine "Next, this product is dissolved in 5 ml of dimethylformamide and the resulting solution is added to the hydrazide solution, then the mixture is stirred at 4 ° C for 7 days. The solvent is distilled off under reduced pressure. About the resulting residue is added water and the oily material obtained as a result is extracted with ethyl acetate. The organic extract is washed with 1N. The solution of hydrochloric acid with water, with a 5% aqueous solution of sodium bicarbonate and with a saturated aqueous solution of sodium chloride in this order, is then dried over anhydrous sodium sulfate. The product is further subjected to condensation by evaporation under reduced pressure. The syrup residue is purified using thin-layer preparative chromatography on silica gel using a mixture in a 5: 1 volume ratio of chloroform and methanol as a developing solvent. The active fractions are extracted with ethyl acetate. The extract is washed with water and with a saturated aqueous solution of sodium chloride, and then dried and condensed, by evaporation under reduced pressure. After diethyl ether is added to the residue, the condensate is cured and then finely ground and collected by filtration, resulting in 02 mg of the title compound as a colorless powder that melts at 206-212 ° C, 0 ° (3, methanol ). Elemental analysis.
Calculated 7.29
G4lH5BN4 ° T Found,%
7.87.

: C 68.9; H 8.13;
C 68.6; H 7
CH2OS-MN
Do-h
he
CONH
PRI me R 2.
M- | 4 (5) -Јm-Benzyloxycarbonyl-3- (1-naphthyl) -L-alanyl-3 - (- thiazolyl) -Bb-alanyl} amino-3 (5) -oxy-6-methyl-heptanoyl) -1, -isoleucine (compound 2).
a) N-Benzyloxycarbonyl-3- (1-naphthyl) -L-alanyl-3- (-thiazolyl) -Pb-alanine hydrazyl.
2.90 g (I, 30 mmol) of L-benzyloxycarbonyl-3- (1-naphthyl) -L-alanine and 2.15 g (8.30 mmol) of chlorohydrate 3
39852
ten
15
20
(4-Thiazolyl) -DL-alanine methyl ester is suspended in CZ ml of anhydrous tetrahydrofuran. At the same time, while cooling with ice, 1.51 ml (9.95 mmol) of diethyl phosphorocyanidate and 3.82 ml (27.4 mmol) of triethylamine n were added to the suspension dropwise under an atmosphere of a stream of nitrogen and the mixture was stirred overnight at room temperature . The reaction product is subjected to condensation by evaporation under reduced pressure. Ethyl acetate is added to the obtained residue and the mixture is washed with water and then dried over anhydrous magnesium sulfate. The solution is evaporated under reduced pressure, the resulting residue is purified on a silica gel chromatography column, and the product is eluted with a mixture in a volume ratio of 10: 1 chloroform and methanol, resulting in 2.62 g (yield 6l ° o) M-benzyloxycarbonyl -3-O-naph-25 tyl) -L-alanyl-3 - (- thiazolyl) -DL-alanine methyl ester,
2.10 g and, About mmol) of this ester is dissolved in 20 ml of dimethylformamide, and then 2S00 g, 0 mmol) of hydrazine hydrate is added, and the mixture is stirred overnight at room temperature. The resulting reaction product was subjected to condensation by evaporation under reduced pressure, and then water was added to the resulting residue. The precipitated crystals are separated by filtration, washed with hexane and diethyl ether, and then dried, resulting in 1.90 g (yield 90.5%) of the title compound.
b) N-Ј4 (S) -Јy-Benzyloxycarbonyl-3- (1-naphthyl) -L-alanyl-3 - (- thiazolyl) - DL-anaHnjf aMHHO-3 (S) -oKCM-6-MeTmirent-nolyl L-isoleucine.
kQQ mg (0.77 mmol) of N-benzyloxycarbonyl-3 (1-naphthyl) -L-alanyl-3-C "-thiazolyl) -DL-alanine hydrazide is suspended in 10 ml of dimethylformamide, and
thirty
35
40
45
50
55
the resulting suspension is cooled to -60 ° C, and at this temperature, 0.66 ml of m of hydrogen chloride solution in dioxane is added. The temperature of the reaction mixture is raised to -20 ° C, and then 0.13 ml (0.97 mmol) of isoamyl nitrite is added, and then the mixture is stirred for 10 minutes. The disappearance of the hydrazide was observed, and then the mixture was again cooled to -60 ° C, after which 0.33 ml (3.00 mmol) of N-methylmorpholine was added to neutralize, then 328 mg (1.02 mmol hydrochloride 4) were added to the mixture. (8) -amino-3 (5) -oxy-6-methylheptanoyl-b-isoleucinol and 0.12 ml (1.09 mmol) of M-methylmorpholine. The solvent is distilled off under reduced pressure, and the resulting residue is purified with using preparative thin layer chromatography on silica gel using a mixture of chloroform and methanol in a 5: 1 volume ratio as a developing p stvoritel, thereby obtaining 310 mg (yield 52%) of the monohydrate of the title compound as white crystals which melt at 167-169 ° C, CoO-p -31,3 ° (, 3 methanol).
Elemental analysis. | Calculated,%: C 63.29; H 7.13; 9.00; S 4.12
C4tH N507S-H20,
Found,%: C 63.38; H 6.84; 9, s 4.12
N
N
PRI me R 3.
About -CH2OSH
CONH CONHCONHON
/
(
4 (S) -Ј and -Benzyloxycarbonyl 3- (1-naphthyl) -L-alanyl-3- (4-thiazolyl) -DL-alanyl amino-3 (5) -oxy-6-methyl-M- (2-morpholinoethyl ) heptanamide (compound 3) "
400 mg (0.77 mmol) of M-benzyloxycarbonyl-3- (1-naphthyl) -L-alanyl-3 (4-thiazolyl) -Bb-alanine hydrazide are suspended in 10 ml of dimethylformamide, then the suspension is cooled to -60 ° At this temperature, 0.66 ml of 4N is added to the suspension at this temperature. solution of hydrogen chloride in dioxane. Then the reaction temperature is raised to -20 ° C and at this temperature 0.13 ml (0.97 mmol) of nitrite isomethyl nitrite is added to the suspension, then the mixture is stirred for 10 minutes. The disappearance of the hydrazide is observed and then the suspension is again cooled to -60 ° C and at
0
0.33 ml (3.00 mmol) of N-methylmorpholine is added to the suspension in order to neutralize this temperature.
At the same time, 4 (8) -tert-butoxycarbonylamino-3 (8) -oxy-6-methylganthanoic acid and (2-morpholinoethyl) - amine are converted to the amide with diethylphosphoric cyanidate and triethylamine. The tert-butoxycarbonyl group is then removed using 6N. solution of hydrogen chloride in dioxane. 4 (5) -amino-3 (8) -oxy-6-methyl-H- (2-morpholinoethyl) heptanamide chlorohydrate is obtained.
350 mg (0.97 mmol) of this compound and 0.22 ml (2.00 mmol) of N-methylmorpholine are added to the reaction mixture obtained above, and then the reaction mixture is stirred overnight at 4 ° C. The solvent is distilled off under reduced pressure, and the resulting residue is purified using preparative thin layer chromatography on silica gel and using a mixture of chloroform and methanol in a volume ratio of 51 as a developing solvent, resulting in 290 mg (7) 195 hydrates of the title compound as white cristae fishing, which melt at 132-13b ° C, 3 (3, methanol).
Elemental analysis.
Calculated,%: C, 61.55; H 6.93; N 10.50; S 4.00.
C4 H52N6OrS 195% 0
Found C, 61.10; H 6.30; N 10.47; S 4.14
four.
five
0
five
0
P
CONH- CONHJ XcONH Y44 OH
(8) - N-Benzyloxycarbonyl-3- (1-mafthyl) -L-alanyl-3- (4-thiazolyl) - DL-alanyl 3-S (3) -ox-6-methyl-N-3 - (-) -2-methylbutylZheptanamide (compound 4).
400 mg (0.77 mmol) of N-benzyloxycarbonyl-3- (1-naphthyl) -M-alanyl-3 (4-TMa3onnn) -DL-anaHHH hydrazine susn are prepared in 10 ml of dimethylformamide
and the 5th suspension is cooled before and at this temperature 0.66 ml of Cn is added. hydrogen chloride in dioxane. The reaction temperature was adjusted to -20 ° C and then 0.13 ml (0.97 mmol) of isoamyl nitrite was added, and the mixture was stirred for 10 minutes.
When the disappearance of the hydrazide was confirmed, the mixture was again cooled to -60 ° C and 0.33 ml (3.00 mmol of tf-methylmorpholine was added to neutralize, followed by the addition of 280 g (1.00 mmol) A (8) -amino-3 ($) - hydroxy-6-methyl-N- (8) - (-) - g-methylbutylheptanamide hydrochloride and 0.12 ml (1.09 mmol) of N-methylmorpholine.
The solvent was distilled off under reduced pressure, and the residue was purified by silica gel thin-layer chromatography using chloroform: methanol in a 5: 1 ratio as a separating solvent, to obtain 29 mg (51%) of the monohydrate of the title compound as white crystals, m.p. 134-137 ° C.
Elemental analysis. Calculated,%: C 6.23; H 7 And:
N
7.06;
(Q CH2OC-NH
yy
-f
AN
CONH9, 36; s 4.29.
C4oHff, N506S-Hzp. Found,%: C 64.00; H
and 9.01; s 4.39
PRI me R 5
Q Q
CONH
gO gon
Y CONH V 4
HE
M- / 4 (5) -H-Benzyloxycarbonyl-3 (1-naphthyl) -b-alanyl-b-histidyl. no-3 (5) -hydroxy-5 cyclohexylpentanoylT-b-isoleucinol (compound 5
Using 315 g (1 mmol) of 4 (5) -t-butoxycarbonylamino-3 (5) -hydroxy-5-cyclohexylpentanoic acid and 129 mg (1.1 mmol) of L-isoleucinol, an N-Ј4 (S) -t tert -butoxycarbonylamino-3 () - hydroxy-5-cyclohexylpen. tanoyl-b-isoleucine as a white powdery substance, 207 mg (0.5 mmol) of which is converted to (5) - k-benzyloxycarbonyl-3- (1 - neftil) -b-alanyl-b-histidyl amino
)
ten
73985210
3 ($) - hydroxy-5-cyclohexylpentanoyl L-isoleucinol. 00.5 mg (0.5 mmol) of the latter was dissolved in a mixture of TO ml of methanol and 0.5 ml of hydrochloric acid in dioxane (n), the solvent was distilled off under reduced pressure, the residue was washed with ethyl acetate and the title product was isolated as chlorohydrate.
Biological tests of the compounds obtained were carried out.
The ability of compounds to inhibit renin 9 activity is released according to the Kokuba method.
The proposed compound is dissolved in 60 bpm / volume aqueous solution of ethanol. The activity of human renin in the presence or absence of each of the compounds is measured using sheep angiotensinogen. The total volume in 1 ml of the mixture for analysis contained 0.1 mol / l / phosphate buffer (pH 7.8), human renin (equivalent to 0.5 kg of antiiotensin 1 per 1 ml / min), angiotene - sheep zenogen (equivalent to 200 ng of angiotensin 1), the indicated concentration of the test compound, 6% ethanol and angiotensinase inhibitors (10 mmol / l sodium ethylenediaminetetraacetate and 3.4 mmol / l 0-hydroxyquinoline).
15
20
thirty
0
The mixture was allowed to react for 10 minutes at 37 ° C, and then the reaction was stopped by placing the tube in a bath of boiling water for 5 minutes. Next, the mixture was centrifuged, and the upper layer (volume from 0.05 to 0.1 ml) was used to analyze the remaining angiotensin 1.
An identical experiment was performed as a control experiment, with the exception that the proposed compound was not used. Based on the values obtained, inhibition of the percentage of renin activity calculated for each test compound was calculated. The results are shown in the table. These values are averages of three to four experiments.
The table shows that the proposed compounds have a significant inhibitory effect on the activity of human renin and are superior to the known compound, Cody-peptide. In this connection, 0
five
obtained under the conditions of the proposed method, in the tested doses, showed no signs of toxicity,

权利要求:
Claims (1)
[1]
Invention Formula
The method of producing peptides of the formula R, CO-III-CH (Cg) -CONH-CH (R5) -X, where R {is a group of the formula
O CH2CH (K) H-C02CH2RYu
R is (C, -C4) -alkyl, (C,.) Is thiazolylalkyl, imidazolylmethyl;
RJ - isobutyl, cyclohexylmethyl;
X is the group CH (ACC) OH;
A is a methylene group;
C - group
-CONHCH2CH2-N () 0;
/
-co-NH-CH, cH-cM, cHj, sn, CH3
—CO — NH — CH — H — CH 2 CHj,
cn he
or their pharmaceutically acceptable salts, having in mind that a carboxylic acid of the general formula
R4 - CO-NH-CHCR -COOH,
where R C and R have the specified banner-i, or its reactive derivative, is subjected to interaction with the amino compound of the general formula
20
H2H-CH (R3) -X, where X and R.J have the indicated meanings.

类似技术:

公开号 | 公开日 | 专利标题

SU1739852A3|1992-06-07|Method for synthesis of peptides or their pharmaceutically acceptable salts

EP0184550B1|1992-03-18|5-amino-4-hydroxy valeryl amide derivatives

US4548926A|1985-10-22|Hypotensive peptides and their use

US4595677A|1986-06-17|Substituted tetrapeptides

US4914129A|1990-04-03|Antihypertensive 5-amino-4-hydroxyvaleryl derivatives substituted by sulphur-containing groups

EP0200406A2|1986-11-05|Novel amino acid derivatives

EP0216539A2|1987-04-01|Novel amino acid derivatives

EP0143746A2|1985-06-05|5-Amino 4-hydroxy-valeryl-substituted derivatives

DE69432573T2|2004-01-08|Endothelin converting enzyme inhibitors

US4656269A|1987-04-07|Histidine derivatives

BG60739B2|1996-01-31|Tripeptides affecting the central nervous system, and method for their preparation

AU626361B2|1992-07-30|Retroviral protease inhibitors

HU204285B|1991-12-30|Process for producing renin-inhibiting polypeptides of small molecule mass and pharmaceutical compositions containing them

US4758584A|1988-07-19|Antihypertensive 5-amino-4-hydroxyvaleryl derivatives substituted by sulphur-containing groups

EP0206807A2|1986-12-30|Novel amino acid derivatives

KR900009022B1|1990-12-17|Non peptidic renin inhibitors

US4346104A|1982-08-24|Novel substituted phenylacetic acid amide compounds

US4420490A|1983-12-13|Substituted phenylacetic acid amide compounds

EP0027260B1|1985-03-13|Peptides, processes for their preparation and pharmaceutical compositions containing them

US4552866A|1985-11-12|Use of diamino alcohols as analgesic agents

CA2043603A1|1991-12-02|Hiv protease inhibitors and processes for their preparation

US5089638A|1992-02-18|Amino acid analogs as CCK-antagonists

US4354966A|1982-10-19|Peptides, process for preparation thereof and use thereof

US5162527A|1992-11-10|Renin inhibitors, processes for preparing them, methods for using them, and compositions containing them

AU638093B2|1993-06-17|Intermediates of peptidylaminodiols

同族专利:

公开号 | 公开日

DK47285D0|1985-02-01|

US4698329A|1987-10-06|

NO850397L|1985-08-05|

CA1267498A|1990-04-03|

NO167744C|1991-12-04|

NO167744B|1991-08-26|

EP0152255A3|1987-06-16|

JPS60163899A|1985-08-26|

FI850429L|1985-08-04|

EP0152255A2|1985-08-21|

HU198951B|1989-12-28|

PT79917A|1985-03-01|

HUT38105A|1986-04-28|

FI850429A0|1985-02-01|

ES8706167A1|1987-06-01|

KR910007576B1|1991-09-28|

ES540110A0|1987-06-01|

KR850006008A|1985-09-28|

DK47285A|1985-08-04|

PT79917B|1987-02-05|

引用文献:

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

NO812612L|1980-08-06|1982-02-08|Ferring Pharma Ltd|ENZYME inhibitor.|

CA1245217A|1981-12-10|1988-11-22|Joshua S. Boger|Renin inhibitory peptides having phe su13 xxdeletion|

DE3377497D1|1982-09-15|1988-09-01|Haessle Ab|Enzyme inhibitors|

WO1984003044A1|1983-02-07|1984-08-16|Ferring Ab|Enzyme inhibitors|

US4613676A|1983-11-23|1986-09-23|Ciba-Geigy Corporation|Substituted 5-amino-4-hydroxyvaleryl derivatives|

DK110285A|1984-03-12|1985-09-13|Pfizer|POLYPEPTIDES AND POLYPEPTIDE DERIVATIVES CONTAINING STATIN OR DERIVATIVES THEREOF AND PHARMACEUTICAL PREPARATIONS|

EP0163237A3|1984-05-29|1988-04-27|Merck & Co. Inc.|Di- and tri-peptidal renin inhibitors|

FI88400C|1984-08-06|1993-05-10|Upjohn Co|FRAMEWORK FOR THE FRAME STATION INHIBITION OF PEPTIDER|

SU1676454A3|1984-11-30|1991-09-07|Санкио Компани Лимитед |Method for peptides preparation of theirs pharmaceutically accessible salts|US4613676A|1983-11-23|1986-09-23|Ciba-Geigy Corporation|Substituted 5-amino-4-hydroxyvaleryl derivatives|

EP0181110A3|1984-10-22|1988-05-11|Kissei Pharmaceutical Co. Ltd.|Histidine derivatives as renin inhibitors|

US4727060A|1984-11-13|1988-02-23|Ciba-Geigy Corporation|Novel 5-amino-4-hydroxyvaleryl derivatives|

EP0184855A3|1984-12-14|1989-05-03|Abbott Laboratories|Resin inhibiting compounds|

EP0190891A3|1985-01-31|1988-04-20|Kissei Pharmaceutical Co. Ltd.|Novel amino acid derivatives|

EP0206807A3|1985-06-28|1988-01-20|Kissei Pharmaceutical Co. Ltd.|Novel amino acid derivatives|

US4853463A|1985-09-04|1989-08-01|Kissei Pharmaceutical Co., Ltd.|Amino acid derivatives|

US4894437A|1985-11-15|1990-01-16|The Upjohn Company|Novel renin inhibiting polypeptide analogs containing S-aryl-D- or L- or DL-cysteinyl, 3-lactic acid or 3-alkyl moieties|

KR870005013A|1985-11-29|1987-06-04|가와무라 요시부미|Lenin-inhibiting oligopeptides, methods of making and uses thereof|

US4885292A|1986-02-03|1989-12-05|E. R. Squibb & Sons, Inc.|N-heterocyclic alcohol renin inhibitors|

FI870474A|1986-02-07|1987-08-08|Ciba Geigy Ag|MED SVAVELHALTIGA GRUPPER SUBSTITUERADE 5-AMINO-4-HYDROXIVALERYLDERIVAT.|

US4727062A|1986-03-17|1988-02-23|Merck & Co., Inc.|3-Halovinylglycine antibacterial agents|

JPH0564948B2|1986-07-11|1993-09-16|Kissei Pharmaceutical|

DE3627877A1|1986-07-30|1988-02-04|Hoechst Ag|RENINE-INHIBITING DI- AND TRIPEPTIDES, METHOD FOR THE PRODUCTION THEREOF, THESE AGENTS AND THEIR USE|

US4814342A|1986-10-31|1989-03-21|Pfizer Inc.|Nor-statine and nor-cyclostatine polypeptides|

DE3640535A1|1986-11-27|1988-06-01|Merck Patent Gmbh|PEPTIDE|

ZW23187A1|1986-12-15|1988-06-29|Hoffmann La Roche|Phosphinic acid derivatives|

EP0274259B1|1986-12-19|1994-02-16|Sankyo Company Limited|New renin-inhibitory oligopeptides, their preparaton and their use|

US5032577A|1986-12-31|1991-07-16|Abbott Laboratories|Peptidylaminodiols|

CH676988A5|1987-01-21|1991-03-28|Sandoz Ag|

US4758584A|1987-02-05|1988-07-19|Ciba-Geigy Corporation|Antihypertensive 5-amino-4-hydroxyvaleryl derivatives substituted by sulphur-containing groups|

GB8707412D0|1987-03-27|1987-04-29|Fujisawa Pharmaceutical Co|Peptide compounds|

US4921855A|1987-06-22|1990-05-01|Fujisawa Pharmaceutical Co., Ltd.|New Histidyl amino acid derivatives, and pharmaceutical composition comprising the same|

US4859654A|1987-07-01|1989-08-22|Pfizer Inc.|Homocyclostatine and cyclostatine containing polypeptides as antihypertensive agents|

DE68916271T2|1988-01-26|1995-02-23|Sankyo Co|Renin inhibiting polypeptides, their production and use.|

EP0383635B1|1989-02-16|1995-07-12|Sankyo Company Limited|Peptides having renin inhibitory activity their preparation and use|

法律状态:

优先权:

申请号 | 申请日 | 专利标题

JP59019100A|JPS60163899A|1984-02-03|1984-02-03|Renin-inhibiting peptide|

[返回顶部]